Intracrystalline Ozurdex® implant: iatrogenic intravitreal injection management

Published:October 04, 2021DOI:
      The intravitreal dexamethasone implant Ozurdex® (Allergan, Inc, Irvine, Calif.) is indicated for the treatment of diabetic macular edema, venous occlusion of the retinal vessels, and noninfectious uveitis. In phakic patients, it is suggested that the injection should be done 4 mm posterior to the corneal limbus, directing the needle to the optic nerve, preferably in the inferotemporal quadrant. Although it is a rare event, inadvertent intracrystalline injection of the dexamethasone implant has been reported in the literature and can lead to complications such as cataract, glaucoma, and visual impairment.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Canadian Journal of Ophthalmology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect